Jennifer J Rhodes sold $83k of ACAD
EVP, CHIEF LEGAL OFFICER, SEC at ACADIA PHARMACEUTICALS INC. 3,844 shares at an average of $21.47, traded Mar 25, 2026, filed Mar 26, 2026.
Score components
- +15RoleOfficer
- +9Trade size$83k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.3%, 3m +10.5%, 6m +3.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001568249-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | MOption exercise Common Stock | +7,515 | $0.00 | $0 | 15,124 | Mar 26, 2026 |
| Mar 25, 2026 | SOpen-market sale Common Stock10b5-1 | -3,844 | $21.47 | $83k | 11,280 | Mar 26, 2026 |
| Mar 24, 2026 | MOption exercise Restricted Stock Unitsderivative | -7,515 | $0.00 | $0 | 22,547 | Mar 26, 2026 |
Related signals
Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $587k 20,141 shares | -27% | |
| 15Weak | ACADIA PHARMACEUTICALS INC | Elizabeth H.Z. Thompson EVP, Head of Research & Dev | $433k 16,558 shares | -47% | |
| 19Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $298k 11,421 shares | -47% | |
| 30Weak | ACADsell ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $114k 5,401 shares | -18% | |
| 0Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $29k 1,332 shares | -4% | |
| 3Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $76k 3,506 shares | -5% | |
| 0Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $23k 1,030 shares | -4% | |
| 9Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $60k 2,709 shares | -4% | |
| 1Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $42k 1,942 shares | -7% | |
| 28Weak | ACADIA PHARMACEUTICALS INC | Catherine E. Owen Chief Executive Officer | $250k 11,641 shares | -44% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.